[{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Xspray Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Axis Clinicals Ltd.","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Hematology","graph2":"Phase I","graph3":"Axis Clinicals Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Axis Clinicals Ltd. \/ Axis Clinicals Ltd."}]

Find Clinical Drug Pipeline Developments & Deals by Axis Clinicals Ltd.

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 27, 2022

                          Lead Product(s) : Dasatinib

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Xspray Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          January 28, 2020

                          Lead Product(s) : Vincristine Sulfate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase I

                          Recipient : Acrotech Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          December 04, 2019

                          Lead Product(s) : Belinostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Acrotech Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 17, 2018

                          Lead Product(s) : Amphotericin B

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : Aurobindo Pharma Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 12, 2016

                          Lead Product(s) : Belinostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Acrotech Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 10, 2016

                          Lead Product(s) : Belinostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Acrotech Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 03, 2015

                          Lead Product(s) : Pralatrexate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Acrotech Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 08, 2014

                          Lead Product(s) : Pralatrexate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Acrotech Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank